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Background: Refractory chronic pain dramatically reduces the quality of life of patients. Existing drugs cannot fully
achieve effective chronic pain control because of their lower efficacy and/or accompanying side effects. Voltage-gated
potassium channels (KCNQ) openers have demonstrated their analgesic effect in preclinical and clinical studies, and are
thus considered to be a potential therapeutic target as analgesics. However, these drugs exhibit a narrow therapeutic
window due to their imposed central nerve system (CNS) side effects. To clarify the analgesic effect by peripheral KCNQ
channel activation, we investigated whether the analgesic effect of the KCNQ channel opener, retigabine, is
inhibited by intracerebroventricular (i.c.v.) administration of the KCNQ channel blocker, 10, 10-bis (4-Pyridinylmethyl)-9
(10H) -anthracenone dihydrochloride (XE-991) in rats.
Results: Oral administration (p.o.) of retigabine showed an anticonvulsant effect on maximal electronic seizures and an
analgesic effect on complete Freund’s adjuvant-induced thermal hyperalgesia. However, impaired motor coordination
and reduced exploratory behavior were also observed at the analgesic doses of retigabine. Administration (i.c.v.) of XE-991
reversed the retigabine-induced anticonvulsant effect, impaired motor coordination and reduced exploratory behavior
but not the analgesic effect. Moreover, intraplantar administration of retigabine or an additional KCNQ channel opener,
N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243), inhibited formalin-induced nociceptive behavior.
Conclusions: Our findings suggest that the peripheral sensory neuron is the main target for KCNQ channel openers to
induce analgesia. Therefore, peripheral KCNQ channel openers that do not penetrate the CNS may be suitable analgesic
drugs as they would prevent CNS side effects.
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Chronic pain is resistant to analgesics, and dramatically re-
duces the quality of life of patients. Non-steroidal anti-
inflammatory drugs and opioids are analgesics used for
acute pain, and also anticonvulsants and antidepressants
are used as supplementary analgesics for convulsions and
depression associated with chronic pain [1-4]. However, all
these drugs cannot fully achieve effective chronic pain con-
trol because of their lower efficacy and/or accompanying
side effects [1-4]. Therefore, development of novel analge-
sics for chronic pain is highly anticipated.
Flupirtine (Katadolon®) is a centrally acting non-opioid
analgesic (available in Germany) for the treatment of a var-
iety of pain states, including chronic pain, such as low back
pain and cancer pain [5-10]. However, flupirtine is not* Correspondence: noboru.tsuchimori@takeda.com
Pharmaceutical Research Division, Inflammation Drug Discovery Unit, Takeda
Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
© 2014 Hayashi et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.universally used because of its side effects on the central
nervous system (CNS), such as somnolence, dizziness,
and nausea [5-10]. Although the mechanism of action of
flupirtine has not yet been fully elucidated, it was recently
reported to inhibit neural excitability via the opening of
voltage-gated potassium channels (KCNQ) [11,12]. There-
fore, the KCNQ channel may be a potential drug target for
analgesics; however, CNS side effects may accompany its
therapeutic effect.
The KCNQ channel consists of four KCNQ subunits
as a homo- or hetero-tetramer [13]. There are five
KCNQ genes coding for five KCNQ subunits, KCNQ1-5
[12]. KCNQ2-5 are expressed in the CNS and peripheral
nervous system (PNS), such as primary afferents [14-19].
Neuronal M-currents are carried via a heteromultimeric
combination of KCNQ2, KCNQ3, and KCNQ5 [20,21],
and are activated at potentials that are at a sub-
threshold for action potential firing and control restingl Ltd. This is an Open Access article distributed under the terms of the Creative
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play an important role in regulating neuronal excitabil-
ity. The relationship of KCNQ channels with the control
of sensory nerve excitability and pain processing is dem-
onstrated by preclinical pharmacological studies using
retigabine, the analogue of flupirtine, which has higher
KCNQ channel opening activity than flupirtine [22-25].
Electrophysiological studies using isolated spinal cord or
small diameter dorsal root ganglion cells have shown
that retigabine raises the threshold of firing by hyperpo-
larizing the membrane potential [23,26,27]. Moreover,
retigabine inhibits spinal dorsal horn neuronal firing rate
induced by electrical stimulation in both naïve and
spinal nerve ligated rats in vivo [23]. In behavioral stud-
ies, retigabine has been reported to exert analgesic ef-
fects in noxious, inflammatory, and neuropathic pain
models [23,28,29]. However, retigabine has displayed
CNS side effects, such as impaired motor coordination
and reduced exploratory behavior at similar doses to
those showing an analgesic effect [30-32].
The KCNQ channel opener, retigabine, has been ap-
proved as a therapeutic drug for refractory partial-onset sei-
zures [33,34]. In clinical trials, dose-limiting CNS side
effects associated with retigabine, such as dizziness, somno-
lence and fatigue were observed at therapeutic doses
[30,35]. An additional KCNQ channel opener, N-(6-chloro-
pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243), is struc-
turally different from retigabine [36,37]. ICA-27243 exhibits
higher selectivity than retigabine as a KCNQ2/3 channel
opener, and also occupies a narrow therapeutic window
against convulsions and CNS side effects [37]. These find-
ings suggest that KCNQ channel opening activity results in
CNS side effects, which may not be prevented by only se-
lectively activating KCNQ2/3. In contrast, KCNQ channel
openers that do not penetrate the CNS are assumed to have
no CNS side effects. However, because the site of action for
their analgesic effect is not fully elucidated, the dissociation
between this effect and CNS side effects remains to be
resolved.
In the present study, we aimed to clarify the site of ac-
tion for the analgesic effect of KCNQ openers by investi-
gating the contribution of brain KCNQ channel opening
activity with reduced exploratory behavior, impaired
motor coordination, and analgesic effects.
Results
Analgesic effect of retigabine and ICA-27243 in CFA-
induced thermal hyperalgesia
Analgesic effects of retigabine (5–20 mg/kg) and ICA-
27243 (3–30 mg/kg) in Complete Freund’s adjuvant
(CFA) -induced thermal hyperalgesia were evaluated by
the plantar test at 30, 60 and 120 min post administration
(Figure 1A, B). Orally administered (p.o.) retigabine or
ICA-27243 dose-dependently increased paw withdrawallatency (PWL) and significantly effects were observed
30 min after administration of 20 mg/kg retigabine or 10
and 30 mg/kg ICA-27243 (p < 0.05).Retigabine and ICA-27243 impaired motor coordination
Vehicle-treated rats spent approximately 60 sec (cut-off
time) on the rod (Figure 2A, B). Compared with vehicle,
orally administered retigabine or ICA-27243 (both at 10,
30, or 100 mg/kg) reduced the running latency on the
rod in a dose-dependent manner. Compared with ve-
hicle, a significantly reduction was observed with 10, 30
or 100 mg/kg retigabine and 30 or 100 mg/kg ICA-
27243 (p < 0.05).Retigabine and ICA-27243 decreased exploratory behavior
Activity counts of exploratory behavior of rats treated with
vehicle prior to retigabine or ICA-27243 administration
were 727 ± 63 or 611 ± 66, respectively (Figure 3A, B).
Compared with vehicle, orally administered retigabine or
ICA-27243 dose-dependently decreased exploratory behav-
ior and significantly effects were observed with 10 or
30 mg/kg retigabine and 10, 30 or 100 mg/kg ICA-27243
(p < 0.05).XE-991 reversed retigabine-induced anticonvulsant
activity
Using the maximal electroshock seizure (MES) test, rats
treated with vehicle were shown to develop tonic convul-
sions (Figure 4A), and the administration of retigabine
dose-dependently reduced these electroshock-induced con-
vulsions. Retigabine inhibited tonic convulsions by approxi-
mately 90%. After intracerebroventricular (i.c.v.) injection
of 80 μg XE-991 20 min beforehand, this inhibition was
reduced to 25% (Figure 4B). The dose of 80 μg/site of
XE-991 was used in the following behavioral tests because
convulsion-like behaviors were sometimes observed after i.
c.v. injection of XE-991 at doses equal to or exceeding
100 μg/site (data not shown).XE-991 reversed retigabine-induced motor coordination
impairment
We next investigated the effect of XE-991 on retigabine-
induced motor coordination impairment via the rotarod
test. Intracerebroventricular injection of saline or XE-991
alone did not affect the latency to fall (mean time on the
rod in both groups = 60 sec [cut-off time], data not shown).
Retigabine reduced the time on rod to 25.1 ± 5.7 sec.
However, after i.c.v. injection of 80 μg XE-991 20 min
beforehand, this reduction was reversed to 56.5 ± 3.1 sec
(Figure 5). These results suggested that opening of brain
KCNQ channels may be responsible for retigabine-induced
motor coordination impairment.
Figure 1 Analgesic effect of retigabine and ICA-27243 in complete Freund’s adjuvant-induced inflammatory pain model. Rats exposed
to retigabine (A) and ICA-27243 (B) at 5, 10 or 20 mg/kg and 3, 10 or 30 mg/kg were tested for PWL 30, 60 and 120 min after the dosing. Each
data was presented as the mean ± S.E.M. of determinations in 6 rats. *p < 0.05 vs vehicle.
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exploratory behavior
XE-991 was then investigated for its effect on retigabine-
mediated reduction of locomotor activity. Intracerebro-
ventricular injection of 80 μg XE-991 alone did not
affect locomotor activity (data not shown). Activity
counts of vehicle-treated rats with saline or XE-991 were
1593 ± 95 or 1762 ± 83, respectively (Figure 6) and the
difference between the two groups was not significant.
Retigabine significantly reduced locomotor counts to
746 ± 101 (p < 0.01). After i.c.v. injection of 80 μg XE-
991 20 min beforehand, this decrease in number was
(yet partially) reversed to 1142 ± 116 (p < 0.05) (Figure 6).
These results indicated that activation of brain KCNQ
channels was partially involved in retigabine-induced re-
duction of exploratory behavior.Figure 2 Retigabine or ICA-27243 impairs motor coordination. Rats adm
were tested for time spent on the rotarod 30 min after the dosing. Each da
*p < 0.05 vs vehicle.XE-991 did not affect retigabine-induced analgesia in an
inflammatory pain model
To determine if KCNQ channel openers produce an an-
algesic effect via the brain, XE-991 was examined for its
effect on retigabine-mediated reversal of CFA-induced
thermal hyperalgesia. The PWL of vehicle-treated rats
with XE-991 was 8.1 ± 0.9 sec while vehicle-treated rats
with saline was 6.2 ± 0.4 sec, and the difference between
the two groups was not significant. Thus XE-991 did not
affect the hyperalgesia (Figure 7). Retigabine-treated rats
exhibited an increase in PWL to 24.7 ± 0.2 sec; however,
after i.c.v. injection of 80 μg XE-991 20 min beforehand,
this effect was not significantly changed (22.4 ± 1.8 sec)
(Figure 7). These results suggested that brain KCNQ
channels may not be involved in retigabine-mediated re-
versal of CFA-induced thermal hyperalgesia.inistered with retigabine (A) and ICA-27243 (B) at 10, 30 or 100 mg/kg
ta was presented as the mean ± S.E.M. of determinations in 6 rats.
Figure 3 Retigabine or ICA-27243 reduces exploratory behavior. Exploratory behavior in rats was quantified 30 min after the treatment with
retigabine (A) and ICA-27243 (B) at 1, 3, 10 or 30 mg/kg and 3, 10, 30 or 100 mg/kg, respectively. Each data was presented as the mean ± S.E.M.,
each mean showed summation for 10 min in 6 rats. *p < 0.05 vs vehicle.
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an analgesic effect
Some reports showed the intraplantar injection of retiga-
bine attenuated bradykinin induced nociceptive behavior,
suggesting that retigabine produces an analgesic effect
via peripheral nerves [38,39]. To confirm the suggestion,
the effect of local injection of retigabine or ICA-27243 was
tested in formalin-induced nociceptive behavior. Retigabine
or ICA-27243 significantly inhibited formalin-induced lick-
ing behavior during the first (0–5 min) and second (10–
30 min) phases (Figure 8). Compared with vehicle, licking
time in the first phase was significantly reduced by 100
or 300 μg/site retigabine by 40% or 25%, respectively
(p < 0.05). Moreover, licking time in the second phase was
significantly reduced by 100 or 300 μg/site retigabine by
38% or 65%, respectively (p < 0.05) (Figure 8A). Similar
significantly results were found with ICA-27243 (p < 0.05)
(Figure 8C): 9% or 29% with 100 or 300 μg/site ICA-
27243, respectively in the first phase, and 13% or 50% withFigure 4 XE-991 reverses retigabine-induced anticonvulsant activity.
tonic extensor convulsions in rats exposed to retigabine at 1–100 mg/kg. (B)
were tested for anticonvulsant activity via the MES test. Retigabine and XE-99
Numbers on top of each column represent the number of rats in which
(N = 10 and 8, respectively).100 or 300 μg/site ICA-27243, respectively in the second
phase. However, administration of retigabine or ICA-27243
(300 μg/site) on the contralateral side did not affect
formalin-induced licking time (Figure 8B and D).
Discussion
Noxious stimuli generate action potentials at peripheral
nerve endings of nociceptive neurons. Impulses that pass
through primary sensory nerves into the spinal cord dor-
sal horn are brought to the cerebral cortex via the spi-
nothalamic tract, thus conveying pain signals [40,41].
Therefore, blocking the action potentials at any region
in this signaling tract would be expected to result in
analgesia. KCNQ channels (except KCNQ1) have been
shown to be expressed in the primary afferent, spinal
cord and brain [14-19]. Retigabine was reported to in-
hibit discharges from isolated brain slices, spinal cord,
small diameter dorsal root ganglion neurons, and injured
peripheral nerve neuroma, and furthermore, in the(A) The maximal electronic seizures (MES) test was used to determine
Retigabine (20 mg/kg)-exposed rats with or without XE-991 (80 μg/site)
1 was administered 30 min and 20 min prior to the MES test, respectively.
tonic extensor convulsions were inhibited out of total number
Figure 5 XE-991 reverses retigabine-induced motor coordination
impairment. Motor coordination impairment was quantified in retigabine
(50 mg/kg)-exposed rats with or without XE-991 (80 μg/site). Retigabine
and XE-991 was administered 30 min and 20 min prior to the behavior
test, respectively. Each data was presented as the mean ± S.E.M. in 10
rats. **p < 0.01.
Figure 6 XE-991 reverses retigabine-induced reduction in
exploratory behavior. Exploratory behavior was assessed in rats
exposed to retigabine (20 mg/kg) with or without XE-991 (80 μg/site).
Retigabine and XE-991 was administered 30 min and 20 min prior
to the behavior test, respectively. Each data was presented as the
mean ± S.E.M. from the 0 to 10 min assessment period (i.e., 30 to 40 min
post-oral administration) in 27 rats. Data were pooled from 3
independent experiments. *p < 0.05, **p < 0.01; N.S., not significant.
Figure 7 XE-991 reversed retigabine-induced analgesia in the
inflammatory pain model. Inflammatory pain was induced by
CFA injection, and 18 hr after CFA injection, PWL was measured in
retigabine (20 mg/kg)-exposed rats with or without XE-991 (80 μg/site).
Retigabine and XE-991 was administered 30 min and 20 min prior to
the behavior test, respectively. Each data was presented as the
mean ± S.E.M. in 5 to 6 rats. *p < 0.05; N.S., not significant.
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XE-991, this response was blocked [23,25-27]. Moreover,
retigabine was shown to improve formalin- or carrageenan-
induced pain in rats, which was completely reversed by sys-
temic XE-991 administration [23,28]. These reports suggest
that KCNQ channel opening activity may produce an anal-
gesic effect by blocking the action potential throughout the
CNS and peripheral nerves. However, the site of action of
KCNQ channel openers is not fully clarified thus far. In this
study, i.c.v. injection of XE-991 did not affect the analgesic
effect of retigabine, despite the same dose preventing
retigabine-mediated inhibition of electro convulsion, sup-
pression of exploratory behavior, and rotarod performance.
These results suggest that KCNQ channel opening in the
brain may play a negligible role in the development of
retigabine-induced analgesia in inflammatory pain. Further-
more, we demonstrated that intraplantar administration of
retigabine or ICA-27243 suppresses formalin-induced lick-
ing behavior. Whereas the contribution of KCNQ channels
in the spinal cord cannot be ruled out, these findings sug-
gest opening of KCNQ channels in only the peripheral
nerves produces sufficient analgesia. In addition, it’s re-
ported that intraplantar injection of retigabine attenuated
bradykinin induced nociceptive behavior [38,39] and that
topical injection of the KCNQ channel opener, flupirtine,
into the sciatic nerve significantly reversed thermal hyper-
algesia in a rat neuropathic pain model induced by partial
sciatic nerve ligation [42]. These reports suggest that per-
ipheral KCNQ channels contribute to pain pathway. More-
over, retigabine has been reported to reduce sensitivity to
noxious heat of nociceptive A-delta fibers using isolated
Figure 8 Analgesic effect of intraplantar administration of retigabine and ICA-27243. Nociceptive behavior was induced by an intraplantar
injection of formalin. Ten min prior to the formalin injection, 100 and 300 μg retigabine and ICA-27243 was injected into intraplantar surface
of the ipsilateral paw (A & C), respectively and of the contralateral paw (B & D), respectively. The duration of licking behavior was recorded
0–10 min (1st phase) and 10–30 min post-formalin injection (2nd phase). Each data was presented as the mean ± S.E.M. in 6 rats. *p < 0.05.
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eral human C-fibers [44]. Furthermore, it’s reported that
intraplantar injection of XE-991 induced nociceptive behav-
ior and increased the responses of A-delta fibers to noxious
heat in the electrophysiological study [38,43,45]. These re-
ports support our hypothesis that KCNQ channel opening
within the peripheral nerves controls hyperalgesia. In con-
trast, Xu et al. [46] reported that i.c.v. injection of retigabine
alleviated CFA-induced inflammatory pain in the temporo-
mandibular joint, suggesting the involvement of brain
KCNQ channels in retigabine-mediated analgesia. The dis-
crepancies between their and our pain models are unclear.
The study of Xu et al. evaluated mechanical allodynia using
von Frey filaments whereas our study evaluated thermal
hyperalgesia. The difference in pain modality may explain
the discrepancy because thermal hyperalgesia during in-
flammation is considered to result from up-regulation and/
or sensitization of the heat-activated channels, transient re-
ceptor potential channel, subfamily vanilloid (TRPV) mem-
ber 1 (TRPV1) and TRPV2, in peripheral nerves [47,48].
Intraplantar injection of formalin in rats is also known to
induce two distinct phases of discharges from spinal dorsal
horn neurons, which modulate nociceptive behavior and
are inhibited by sciatic nerve block [49]. In the CFA-
induced inflammatory pain model, inflammatory mediators
directly and/or indirectly activate non-selective cation
channels (such as TRPV1 and transient receptor potentialchannel, subfamily A member 1) in Aδ fiber and/or C fibers
of primary sensory nerves and thus depolarize neurons
[50-52]. The depolarization induces action potentials and
causes pain. These findings suggest that both formalin-
induced nociceptive responses and CFA-induced pain
behavior are caused by action potentials of primary sensory
nerves. Retigabine is reported to hyperpolarize the resting
membrane potential of primary sensory neurons [23].
Therefore, retigabine is considered to control membrane
depolarization and inhibit excessive discharges from in-
flamed peripheral nerves, thus exhibiting its analgesic effect.
This idea is consistent with our present results that intra-
plantar administration of retigabine inhibited formalin-
induced nociceptive responses and i.c.v. injection of
XE-991 did not affect the analgesic effect of retigabine on
CFA-induced pain.
Retigabine activates all members of the KCNQ channel
family except KCNQ1 [12]. ICA-27243 shows more se-
lective activity than retigabine for the KCNQ2/3 subtype
by binding to a different site on the KCNQ channel
[36,37,53,54]. Roeloffs et al. [37] reported that the anti-
convulsant efficacy of ICA-27243 in rodent models was
at doses significantly less than those shown to affect
open-field locomotor activity or the ability to remain on
the rotarod. However, in the present study, ICA-27243
produced an analgesic effect as well as reduced explora-
tory behavior and impaired motor coordination at the
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of a KCNQ channel opener toward KCNQ2/3 may be
insufficient to separate its analgesic effect with its poten-
tial CNS side effects.
In the current study, XE-991 significantly, but only
partially, reversed retigabine-induced reduction of ex-
ploratory behavior compared with that of motor coord-
ination. The reason for the difference between the two
responses is unknown. However, retigabine has been re-
ported to allosterically enhance gamma-aminobutyric
acid (GABA) activity for GABA subtype A (GABAA)
receptors [55-57]. The GABAA agonist, diazepam, was
also reported to reduce locomotor activity [58]. There-
fore, enhancement of GABAA activity by retigabine may
partially contribute to the reduction of exploratory be-
havior, thus possibly explaining our observation with
XE-991 in the present study.
Conclusion
This study is the first to suggest that peripheral sensory
neurons may be the main target for KCNQ channel
openers to induce analgesia. Therefore, development of
peripheral KCNQ channel openers that do not penetrate
the CNS may provide novel analgesic drugs without
CNS side effects. While in principal this may be possible
with some future KCNQ channel openers, it is unlikely
to work for retigabine analogs since retigabine has to
penetrate the cell membrane in order to access its bind-
ing site on the KCNQ channel [59].
Methods
Animals
Adult (6 weeks old) male Sprague–Dawley rats (180–
220 g) were purchased from Nihon Clea (Yokohama,
Japan) and used according to experimental protocols ap-
proved by Takeda’s Experimental Animal Care and Use
Committee. The animals were housed in group cages
(five rats per cage) under a 12:12 h light/dark cycle
(room temperature between 21 and 24.8°C). Water and
laboratory chow (type MF; Oriental Yeast Co., Tokyo,
Japan) were available ad libitum.
Surgery for i.c.v. injection
Rats were anesthetized with pentobarbital (50 mg/kg, in-
traperitoneally) and placed in a stereotaxic apparatus.
For i.c.v. cannulation, a small hole was made in the skull
with a dental drill and a stainless steel guide cannula
(AG-4; Eicom, Kyoto, Japan) was implanted according to
stereotaxic coordinates as follows: anterior-posterior =
−0.8 mm from bregma, medial-lateral = 1.6 mm right
from lambda and dorsal-ventral = 3.8 mm from the skull
surface. The guide cannula was set in the skull, and se-
cured with unifast III (03-G0110; GC Corporation).
After surgery, the animals were set with a dummy-cannula (AD-4; Eicom) and cap-nut (AC-1; Eicom), and
bred (approximately 1 week) in the individual-cage until
the day of the experiment. For i.c.v. injection of drugs,
the stereo adapter (SAG-10; Eicom) was connected to
the Hamilton syringe (80601) through a microinjection
tube (JT-10; Eicom), which was inserted in the guide
cannula.
MES test
An electrical stimulus (via ear clip electrodes with a
shock level of 95 mA and 100 Hz, and duration of 2 sec)
was applied by the ECT unit generator (model 7801 Ugo
Basile, Varese, Italy). The stimulation was delivered
30 min after the oral administration of retigabine be-
cause the peak of the effect was observed at that time
(data not shown). The maximal tonic extension of the
hind limbs (tonic extensor convulsions) was taken as an
endpoint. If the tonic extensor convulsions did not occur
within 5 sec, the animal was regarded to be protected. In
control groups (i.e. vehicle treatment) all animals exhib-
ited tonic extension of hind limbs. Therefore, percent in-
hibition of tonic extensor convulsion was determined by
the percentage of the number of the protected animal to
the total number.
Measurement of PWL to thermal stimuli
Rats were placed individually in a clear plastic box on an
elevated floor of heat-tempered clear glass (Plantar test,
Ugo basile, Varese, Italy). After 30 min of habituation,
infrared radiant heat source was focused on the plantar
surface of right hind paw. The time of foot withdrawal
from the beam of light was measured. The cut-off time
in the absence of a response was 25 sec to avoid tissue
damage by heating.
CFA-induced inflammatory pain model
Before CFA injection (−18 hr), baseline PWL was mea-
sured, and rats except that with short (< 15 sec) or long
(>25 sec) PWL were subcutaneously injected with
200 μL CFA (Sigma-Aldrich, St.Louis, MO) in the plan-
tar surface of the right hind paw using a syringe and a
25-gauge needle. Before administration of compounds
(18 h after CFA injection; 0 min), rats were assessed for
thermal hyperalgesia, and those with short PWL (< 10 sec)
were exposed to the compounds.
Assessment of exploratory behavior
Locomotor activity was automatically measured using
Supermex (Muromachi Kikai, Tokyo, Japan). Rats were
administered with either vehicle or the compounds
and then temporarily returned to their home cages. To
measure their exploratory behavior in a novel environ-
ment, the animals were not habituated to the testing
cages prior to the experiment. Thirty minutes after oral
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placed in test cages for 10 min, and locomotor activities
were automatically measured using Supermex.Rotarod test
The rotarod test was performed on a rotary apparatus
that consisted of a rod (4.3 cm in diameter) suspended
horizontally 50 cm above a plane working area. Circular
acrylic plate separators were placed at 20-cm intervals
along the rod. The rod turned at 18 revolutions per min.
Rats were pre-trained 2 days before the experiments,
and those that only remained on the rod for 60 sec in at
least one of three trials were used in the experiments.
The trials (1-min duration) were performed three times
and the average time that the animal remained on the
rod (≤ 60 sec) was calculated.Formalin test
Retigabine and ICA-27243 were dissolved in saline
(10% v/v), containing ethanol (20% v/v), Tween 80
(70% v/v). Drug solution or corresponding vehicle (50 μL)
was subcutaneously injected in the plantar surface of the
right hind paw. Ten minutes after drug administration,
the animals then received a subcutaneous injection of
2.5% formalin (50 μL) in the plantar surface of the
ipsilateral or contralateral hind paw. A biphasic licking of
the injected paw was observed, and the duration of licking
was recorded 0–10 min (1st phase) and 10–30 min
post-formalin injection (2nd phase).Drugs
Retigabine and ICA-27243 (synthesized in the Medicinal
Chemistry Research Laboratories of Takeda Pharmaceut-
ical Company, Osaka, Japan) were formulated in methyl-
cellulose, and administered orally (5 mL/kg) 30 min
prior to the behavioral test, unless otherwise stated. Reti-
gabine was orally administrated 50 mg/kg in XE-991
combination rotarod study and 20 mg/kg in another
combination study. The selective Kv7 blocker was 10,
10-bis (4-Pyridinylmethyl)-9(10H)-anthracenone dihy-
drochloride (XE-991) (TOCRIS bioscience, Bristol, UK).
XE-991 was dissolved in saline, and administered (i.c.v.)
(20 μL total volume, infusion rate of 40 μL/min) 20 min
prior to the behavioral test.Statistical analysis
Data are expressed as the mean ± S.E.M. Between-group
differences were analyzed with the Williams’ test,
Shirley-Williams test, Dunnett’s test, non-parametric
Dunnett’s test, Student’s t-test or Welch’s t-test. Signifi-
cance was reached at values of p < 0.05 and p < 0.01.Abbreviations
CNS: Central nervous system; i.c.v.: Intracerebroventricular; CFA: Complete
Freund’s adjuvant; PWL: Paw withdrawal latency; MES: Maximal electroshock
seizure.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HH designed and contributed all experiments and performed MES test,
locomotor activity test and plantar test and analysed these experiments data.
MI designed and performed rota rod test and formalin test and analysed
these experiments data. TM contributed to all experiments design and
supervised research. HH wrote the manuscript. Above all authors and NT
contributed read and approved the final manuscript.
Acknowledgements
We thank Drs. Yoshinori Ikeura and Youichi Nishikawa for providing us with
retigabine and ICA-27243.
Received: 28 October 2013 Accepted: 10 February 2014
Published: 21 February 2014
References
1. Bryant L, Doyle T, Chen Z, Cuzzocrea S, Masini E, Vinci MC, Esposito E,
Mazzon E, Petrusca DN, Petrache I, Salvemini D: Spinal ceramide and
neuronal apoptosis in morphine antinociceptive tolerance. Neurosci Lett
2009, 463:49–53.
2. Farooq M, Haq I, Qureshi AS: Cardiovascular risks of COX inhibition:
current perspectives. Expert Opin Pharmacother 2008, 9:1311–1319.
3. Juni P, Rutjes AW, Dieppe PA: Are selective COX 2 inhibitors superior to
traditional non steroidal anti-inflammatory drugs? BMJ 2002, 324:1287–1288.
4. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH: Algorithm for
neuropathic pain treatment: an evidence based proposal. Pain 2005,
118:289–305.
5. Luben V, Muller H, Lobisch M, Worz R: [Treatment of tumor pain with
flupirtine. Results of a double-blind study versus tramadol]. Fortschr Med
1994, 112:282–286.
6. Scheef W: Analgesic efficacy and safety of oral flupirtine in the treatment
of cancer pain. Postgrad Med J 1987, 63(Suppl 3):67–70.
7. Scheef W, Wolf-Gruber D: [Flupirtine in patients with cancer pain].
Arzneimittelforschung 1985, 35:75–77.
8. Mastronardi P, D’Onofrio M, Scanni E, Pinto M, Frontespezi S, Ceccarelli MG,
Bianchi F, Mazzarella B: Analgesic activity of flupirtine maleate: a controlled
double-blind study with diclofenac sodium in orthopaedics.
J Int Med Res 1988, 16:338–348.
9. Riethmuller-Winzen H: Flupirtine in the treatment of post-operative pain.
Postgrad Med J 1987, 63(Suppl 3):61–65.
10. Moore RA, Bullingham RE, Simpson S, O’Sullivan G, Evans PJ, McQuay HJ,
Lloyd JW: Comparison of flupirtine maleate and dihydrocodeine in
patients following surgery. Br J Anaesth 1983, 55:429–432.
11. Friedel HA, Fitton A: Flupirtine. A review of its pharmacological properties, and
therapeutic efficacy in pain states. Drugs 1993, 45:548–569.
12. Gribkoff VK: The therapeutic potential of neuronal KCNQ channel
modulators. Expert Opin Ther Targets 2003, 7:737–748.
13. Delmas P, Brown DA: Pathways modulating neural KCNQ/M (Kv7)
potassium channels. Nat Rev Neurosci 2005, 6:850–862.
14. Jentsch TJ: Neuronal KCNQ potassium channels: physiology and role in
disease. Nat Rev Neurosci 2000, 1:21–30.
15. Dalby-Brown W, Hansen HH, Korsgaard MP, Mirza N, Olesen SP: K(v)7
channels: function, pharmacology and channel modulators. Curr Top Med
Chem 2006, 6:999–1023.
16. Saganich MJ, Machado E, Rudy B: Differential expression of genes
encoding subthreshold-operating voltage-gated K + channels in brain.
J Neurosci 2001, 21:4609–4624.
17. Yang WP, Levesque PC, Little WA, Conder ML, Ramakrishnan P, Neubauer
MG, Blanar MA: Functional expression of two KvLQT1-related potassium
channels responsible for an inherited idiopathic epilepsy. J Biol Chem
1998, 273:19419–19423.
Hayashi et al. Molecular Pain 2014, 10:15 Page 9 of 9
http://www.molecularpain.com/content/10/1/1518. Cooper EC, Harrington E, Jan YN, Jan LY: M channel KCNQ2 subunits are
localized to key sites for control of neuronal network oscillations and
synchronization in mouse brain. J Neurosci 2001, 21:9529–9540.
19. Dedek K, Kunath B, Kananura C, Reuner U, Jentsch TJ, Steinlein OK: Myokymia
and neonatal epilepsy caused by a mutation in the voltage sensor of the
KCNQ2 K+ channel. Proc Natl Acad Sci U S A 2001, 98:12272–12277.
20. Brown DA, Passmore GM: Neural KCNQ (Kv7) channels. Br J Pharmacol
2009, 156:1185–1195.
21. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, Dixon JE,
McKinnon D: KCNQ2 and KCNQ3 potassium channel subunits: molecular
correlates of the M-channel. Science 1998, 282:1890–1893.
22. Martire M, Castaldo P, D’Amico M, Preziosi P, Annunziato L, Taglialatela M: M
channels containing KCNQ2 subunits modulate norepinephrine, aspartate,
and GABA release from hippocampal nerve terminals. J Neurosci 2004,
24:592–597.
23. Passmore GM, Selyanko AA, Mistry M, Al-Qatari M, Marsh SJ, Matthews EA,
Dickenson AH, Brown TA, Burbidge SA, Main M, Brown DA: KCNQ/M
currents in sensory neurons: significance for pain therapy. J Neurosci
2003, 23:7227–7236.
24. Rivera-Arconada I, Lopez-Garcia JA: Effects of M-current modulators on the
excitability of immature rat spinal sensory and motor neurones. Eur J
Neurosci 2005, 22:3091–3098.
25. Roza C, Lopez-Garcia JA: Retigabine, the specific KCNQ channel opener,
blocks ectopic discharges in axotomized sensory fibres. Pain 2008,
138:537–545.
26. Rivera-Arconada I, Martinez-Gomez J, Lopez-Garcia JA: M-current modula-
tors alter rat spinal nociceptive transmission: an electrophysiological
study in vitro. Neuropharmacology 2004, 46:598–606.
27. Rivera-Arconada I, Lopez-Garcia JA: Retigabine-induced population
primary afferent hyperpolarisation in vitro. Neuropharmacology 2006,
51:756–763.
28. Blackburn-Munro G, Jensen BS: The anticonvulsant retigabine attenuates
nociceptive behaviours in rat models of persistent and neuropathic pain.
Eur J Pharmacol 2003, 460:109–116.
29. Dost R, Rostock A, Rundfeldt C: The anti-hyperalgesic activity of retigabine
is mediated by KCNQ potassium channel activation. Naunyn
Schmiedebergs Arch Pharmacol 2004, 369:382–390.
30. Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, Blackburn-Munro
RE: Retigabine: chemical synthesis to clinical application. CNS Drug Rev 2005,
11:1–20.
31. Tober C, Rostock A, Rundfeldt C, Bartsch R: D-23129: a potent
anticonvulsant in the amygdala kindling model of complex partial
seizures. Eur J Pharmacol 1996, 303:163–169.
32. Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strobaek D, Mirza NR: Anxiolytic
effects of Maxipost (BMS-204352) and retigabine via activation of neuronal
Kv7 channels. J Pharmacol Exp Ther 2005, 314:282–292.
33. Yamada M, Welty TE: Ezogabine: an evaluation of its efficacy and safety
as adjunctive therapy for partial-onset seizures in adults. Ann
Pharmacother 2012, 46:1358–1367.
34. Ciliberto MA, Weisenberg JL, Wong M: Clinical utility, safety, and
tolerability of ezogabine (retigabine) in the treatment of epilepsy.
Drug Healthc Patient Saf 2012, 4:81–86.
35. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS: Progress
report on new antiepileptic drugs: a summary of the Ninth Eilat
Conference (EILAT IX). Epilepsy Res 2009, 83:1–43.
36. Padilla K, Wickenden AD, Gerlach AC, McCormack K: The KCNQ2/3 selective
channel opener ICA-27243 binds to a novel voltage-sensor domain site.
Neurosci Lett 2009, 465:138–142.
37. Roeloffs R, Wickenden AD, Crean C, Werness S, McNaughton-Smith G,
Stables J, McNamara JO, Ghodadra N, Rigdon GC: In vivo profile of ICA-27243
[N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective
KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models.
J Pharmacol Exp Ther 2008, 326:818–828.
38. Liu B, Linley JE, Du X, Zhang X, Ooi L, Zhang H, Gamper N: The acute
nociceptive signals induced by bradykinin in rat sensory neurons are
mediated by inhibition of M-type K + channels and activation of Ca2 +
−activated Cl- channels. J Clin Invest 2010, 120:1240–1252.
39. Mi Y, Zhang X, Zhang F, Qi J, Gao H, Huang D, Li L, Zhang H, Du X: The
role of potassium channel activation in celecoxib-induced analgesic
action. PLoS One 2013, 8:e54797.40. Woolf CJ, Ma Q: Nociceptors–noxious stimulus detectors. Neuron 2007,
55:353–364.
41. Hucho T, Levine JD: Signaling pathways in sensitization: toward a
nociceptor cell biology. Neuron 2007, 55:365–376.
42. Rose K, Ooi L, Dalle C, Robertson B, Wood IC, Gamper N: Transcriptional
repression of the M channel subunit Kv7.2 in chronic nerve injury.
Pain 2011, 152:742–754.
43. Passmore GM, Reilly JM, Thakur M, Keasberry VN, Marsh SJ, Dickenson AH,
Brown DA: Functional significance of M-type potassium channels in
nociceptive cutaneous sensory endings. Front Mol Neurosci 2012, 5:63.
44. Lang PM, Fleckenstein J, Passmore GM, Brown DA, Grafe P: Retigabine
reduces the excitability of unmyelinated peripheral human axons.
Neuropharmacology 2008, 54:1271–1278.
45. Linley JE, Rose K, Patil M, Robertson B, Akopian AN, Gamper N: Inhibition of M
current in sensory neurons by exogenous proteases: a signaling pathway
mediating inflammatory nociception. J Neurosci 2008, 28:11240–11249.
46. Xu W, Wu Y, Bi Y, Tan L, Gan Y, Wang K: Activation of voltage-gated KCNQ/Kv7
channels by anticonvulsant retigabine attenuates mechanical allodynia of
inflammatory temporomandibular joint in rats. Mol Pain 2010, 6:49.
47. Carlton SM, Coggeshall RE: Peripheral capsaicin receptors increase in the
inflamed rat hindpaw: a possible mechanism for peripheral sensitization.
Neurosci Lett 2001, 310:53–56.
48. Shimosato G, Amaya F, Ueda M, Tanaka Y, Decosterd I, Tanaka M:
Peripheral inflammation induces up-regulation of TRPV2 expression in
rat DRG. Pain 2005, 119:225–232.
49. Pitcher GM, Henry JL: Second phase of formalin-induced excitation of
spinal dorsal horn neurons in spinalized rats is reversed by sciatic nerve
block. Eur J Neurosci 2002, 15:1509–1515.
50. Xiao WH, Bennett GJ: C-fiber spontaneous discharge evoked by chronic
inflammation is suppressed by a long-term infusion of lidocaine yielding
nanogram per milliliter plasma levels. Pain 2008, 137:218–228.
51. Ma W, Quirion R: Inflammatory mediators modulating the transient receptor
potential vanilloid 1 receptor: therapeutic targets to treat inflammatory and
neuropathic pain. Expert Opin Ther Targets 2007, 11:307–320.
52. Wang S, Dai Y, Fukuoka T, Yamanaka H, Kobayashi K, Obata K, Cui X,
Tominaga M, Noguchi K: Phospholipase C and protein kinase A mediate
bradykinin sensitization of TRPA1: a molecular mechanism of
inflammatory pain. Brain 2008, 131:1241–1251.
53. Schenzer A, Friedrich T, Pusch M, Saftig P, Jentsch TJ, Grotzinger J, Schwake
M: Molecular determinants of KCNQ (Kv7) K + channel sensitivity to the
anticonvulsant retigabine. J Neurosci 2005, 25:5051–5060.
54. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H: The new
anticonvulsant retigabine favors voltage-dependent opening of the
Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol
2005, 67:1009–1017.
55. Kapetanovic IM, Yonekawa WD, Kupferberg HJ: The effects of D-23129,
a new experimental anticonvulsant drug, on neurotransmitter amino
acids in the rat hippocampus in vitro. Epilepsy Res 1995, 22:167–173.
56. van Rijn CM, Willems-van Bree e: Synergy between retigabine and GABA
in modulating the convulsant site of the GABAA receptor complex. Eur J
Pharmacol 2003, 464:95–100.
57. Wickenden AD, Roeloffs R, McNaughton-Smith G, Rigdon GC: KCNQ potassium
channels: drug targets for the treatment of epilepsy and pain. Expert Opin Ther
Pat 2004, 14:457–469.
58. Vlainic J, Pericic D: Effects of acute and repeated zolpidem treatment on
pentylenetetrazole-induced seizure threshold and on locomotor activity:
comparison with diazepam. Neuropharmacology 2009, 56:1124–1130.
59. Tatulian L, Brown DA: Effect of the KCNQ potassium channel opener
retigabine on single KCNQ2/3 channels expressed in CHO cells. J Physiol
2003, 549:57–63.
doi:10.1186/1744-8069-10-15
Cite this article as: Hayashi et al.: Activation of peripheral KCNQ
channels attenuates inflammatory pain. Molecular Pain 2014 10:15.
